ArticleFrontiers in oncology2022

Vemurafenib inhibits immune escape biomarker BCL2A1 by targeting PI3K/AKT signaling pathway to suppress breast cancer.

Yalan Dai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.